Literature DB >> 16946355

Strategies for discontinuing long-term benzodiazepine use: meta-analysis.

Richard C Oude Voshaar1, Jaap E Couvée, Anton J L M van Balkom, Paul G H Mulder, Frans G Zitman.   

Abstract

BACKGROUND: The prevalence of benzodiazepine consumption in European countries remains at 2-3% of the general population despite the well-documented disadvantages of long-term use. AIMS: To review systematically the success rates of different benzodiazepine discontinuation strategies.
METHOD: Meta-analysis of comparable intervention studies.
RESULTS: Twenty-nine articles met inclusion criteria. Two groups of interventions were identified; minimal intervention (e.g. giving simple advice in the form of a letter or meeting to a large group of people; n=3), and systematic discontinuation (defined as treatment programmes led by a physician or psychologist; n=26). Both were found to be significantly more effective than treatment as usual: minimal interventions (pooled OR=2.8, 95% CI 1.6-5.1); systematic discontinuation alone (one study, OR=6.1, 95% CI 2.0-18.6). Augmentation of systematic discontinuation with imipramine (two studies, OR=3.1, 95% CI 1.1-9.4) or group cognitive-behavioural therapy for patients with insomnia (two studies, OR=5.5, 95% CI 2.3-14.2) was superior to systematic discontinuation alone.
CONCLUSIONS: Evidence was found for the efficacy of stepped care (minimal intervention followed by systematic discontinuation alone) in discontinuing long-term benzodiazepine use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946355     DOI: 10.1192/bjp.189.3.213

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  48 in total

Review 1.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

Review 2.  Deprescribing Benzodiazepines in Older Patients: Impact of Interventions Targeting Physicians, Pharmacists, and Patients.

Authors:  Brendan J Ng; David G Le Couteur; Sarah N Hilmer
Journal:  Drugs Aging       Date:  2018-06       Impact factor: 3.923

3. 

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

Review 4.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

5.  Efficacy of CBT for benzodiazepine discontinuation in patients with panic disorder: Further evaluation.

Authors:  Michael W Otto; R Kathryn McHugh; Naomi M Simon; Frank J Farach; John J Worthington; Mark H Pollack
Journal:  Behav Res Ther       Date:  2010-04-28

6.  Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

Authors:  Ritva Lähteenmäki; Juha Puustinen; Tero Vahlberg; Alan Lyles; Pertti J Neuvonen; Markku Partinen; Ismo Räihä; Sirkka-Liisa Kivelä
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

7.  PURLs: patient overusing antianxiety meds? Say so (in a letter).

Authors:  Robert Levy; Shailendra Prasad
Journal:  J Fam Pract       Date:  2012-11       Impact factor: 0.493

8.  Feasibility of discontinuing chronic benzodiazepine use in nursing home residents: a pilot study.

Authors:  Jolyce Bourgeois; Monique M Elseviers; Luc Van Bortel; Mirko Petrovic; Robert H Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2014-08-08       Impact factor: 2.953

Review 9.  Withdrawing Benzodiazepines in Patients With Anxiety Disorders.

Authors:  Malcolm Lader; Andri Kyriacou
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

10.  Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

Authors:  Kevin Pottie; Wade Thompson; Simon Davies; Jean Grenier; Cheryl A Sadowski; Vivian Welch; Anne Holbrook; Cynthia Boyd; Robert Swenson; Andy Ma; Barbara Farrell
Journal:  Can Fam Physician       Date:  2018-05       Impact factor: 3.275

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.